gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · GLUEHealthcareBiotechnology

Monte Rosa Therapeutics, Inc. Common Stock (GLUE)

$10.82+3.94%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$10.82▼ 9.83% in range
Nov 4, 2025Low $9.74 · High $25.31Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Monte Rosa Therapeutics closed at $10.82 on Nov 4, up 3.94%, 57.3% below its 52-week closing high. Volume of 2.0M shares was 1.28× its 20-day average (above normal).

Split-adjusted performance: +9.6% over one month, -46.9% over six months, -10.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $8.97M, down 61.3% from a year earlier, with a net margin of -483.9%.

Short interest was 20.7M shares at the Oct 15 settlement, up 4.9% from the prior report (41.9% of float, 11.2 days to cover).

Market cap$923.1M85.3M shares
Revenue · quarter$9.0M−61.3% YoY
Diluted EPS$-0.43—
P/E · TTM—P/S 32.1×
Net margin-483.9%Gross 100.0%
Dividend yieldNone
52-week range9.74 – 25.31−57.3% from high
Volume2.0M1.28× 20-day avg
Volatility · 60d53.3%Annualised
Short % of float41.9%11.2 days to cover
Net cash$621.1MCash $621.1M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.3%1M +9.6%3M −31.1%6M −46.9%YTD −31.0%1Y −10.4%3Y +249.0%5Y −58.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum31
Revenue growth19
Net margin42
Value (low P/E)—
Size72

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short20.7M+4.9% vs prior
Days to cover11.2Settled Oct 15
% of float41.9%
Short vol. 10d57.6%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
GLUEMonte Rosa Therapeutics$10.82+3.94%−46.9%−61.3%−483.9%—$923.1M
ODTXOdyssey Therapeutics$19.50−9.60%————$937.1MCompare
MGTXMeiraGTx Holdings$9.42−1.05%−4.8%+8608.6%50.0%11.5$904.7MCompare
PRMEPrime Medicine$4.97+9.23%+45.7%+3.5%−3649.0%—$901.4MCompare
CGEMCullinan Therapeutics$12.49−20.70%−16.7%———$803.8MCompare
DNAGinkgo Bioworks Holdings$11.65+8.27%+15.6%−48.5%−231.7%—$784.5MCompare
SANASana Biotechnology$2.56+4.92%−29.7%———$766.4MCompare
ATTOAttovia Therapeutics$15.60+2.16%————$712.2MCompare
SLDBSolid Biosciences$6.52+3.82%−9.4%———$699.1MCompare

News about Monte Rosa Therapeutics

All news →
Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?Zacks Investment Research · 1d ago▲ PositiveAre Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?Zacks Investment Research · Oct 23, 2026▼ NegativeMonte Rosa Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · May 20, 2026▲ Positive

Quick answers

What does Monte Rosa Therapeutics do?
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs.
What is GLUE's market cap?
$923.09M, based on the Nov 4 close of $10.82.
Does Monte Rosa Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of GLUE is sold short?
20.7M shares, 41.9% of float, as of Oct 15, 2026.
What sector is GLUE in?
Healthcare, in the Biotechnology industry.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

HQ: Boston, MA173 employeesListed Jun 24, 2021monterosatx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology